Prevention of left ventricular remodelling after acute myocardial infarction: An update

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 3, 2010, Pages 196-207

  Rossini, Roberta ^a   Senni, Michele ^a   Musumeci, Giuseppe ^a   Ferrazzi, Paolo ^a   Gavazzi, Antonello ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Ace inhibitors; Acute myocardial infarction; Aldosterone antagonists; Angiotensin receptor blockers; Beta blockers; Left ventricular remodelling; Primary coronary angioplasty

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BOSENTAN; CANRENONE; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LISINOPRIL; LOSARTAN; MATRIX METALLOPROTEINASE; METOPROLOL; NEBIVOLOL; PERINDOPRIL; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SPIRONOLACTONE; TIMOLOL; TRANDOLAPRIL; VALSARTAN;

ACUTE HEART INFARCTION; ARTICLE; CELL TRANSFER; CLINICAL TRIAL; ENZYME ACTIVATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; NO REFLOW PHENOMENON; OXIDATIVE STRESS; PATENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; ENZYME ACTIVATORS; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; STEM CELL TRANSPLANTATION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 78650020369     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010793351999     Document Type: Article

References (137)

1. Adams JE III, Sicard GA, Allen BT, Bridwell KH, Lenke LG, Dávila-Román VG, et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330: 670-4.
2. Franzosi MG, Santoro E, De Vita C, Geraci E, Lotto A, Maggioni AP, et al. On behalf of the GISSI investigators ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1. Study Circulation 1998; 98: 2659-65.
3. GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogenactivator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-68.
4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
5. Lamas GA, Flaker GC, Mitchell G, Smith SC Jr, Gersh BJ, Wun CC, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. The survival and ventricular enlargement investigators. Circulation 1995; 92: 1101-9.
6. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-209.
7. Anthonio RL, van Veldhuisen DJ, van Gilst WH. Left ventricular dilatation after myocardial infarction: ACE inhibitors, betablockers, or both? J Cardiovasc Pharmacol 1998; 32 (Suppl 1): S1-8.
8. Orn S, Manhenke C, Anand IS, Squire I, Nagel E, Edvardsen T, et al. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol 2007; 99: 1109-14.
9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-82.
10. Anversa P, Loud AV, Levicky V, Guideri G. Left ventricular failure induced by myocardial infarction. I Myocyte hypertrophy. Am J Physiol 1985; 248: H876-82.
11. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodelling in the year after first anterior myocardial infarction: A quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992; 19: 1136-44.
12. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, et al. Left ventricular remodelling after myocardial infarction: A corollary to infarct expansion. Circulation 1986; 74: 693-702.
13. Zimmerman SD, Criscione J, Covell JW. Remodelling in myocardium adjacent to an infarction in the pig left ventricle. Am J Physiol Heart Circ Physiol 2004; 287: H2697 -704.
14. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 1996; 125: 605-13.
15. [Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute myocardial infarction: Effect of timing and modulating factors in experimental models. Am J Cardiol 1993; 72: 13G-21G.
16. Sun Y. Intracardiac rennin-angiotensin system and myocardial repair/remodelling following infarction. J Mol Cel Card 2010; 48: 483-9.
17. Takemura G, Fujiwara H. Role of apoptosis in remodelling after myocardial infarction. Pharmacol Ther 2004; 104: 1-16.
18. Passier RC, Smits JF, Verluyten MJ, Studer R, Drexler H, Daemen MJ. Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Am J Physiol 1995; 269: H1268-76.
19. Sun Y, Zhang JQ, Zhang J, Lamparter S. Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 2000; 135: 316-23.
20. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995; 147: 325-38.
21. Brodie B, Stuckey T D, Kissling G, Hansen CJ, Weintraub RA, Kelly TA. Importance of infarct-related artery patency for recovery of left ventricular function and late survival after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1996; 28: 319-25.
22. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? Circulation 1989; 79: 441-4.
23. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010; 55: 1649-60.
24. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-705.
25. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-508.
26. Gerber BL, Rochitte CE, Melin JA, McVeigh ER, Bluemke DA, Wu KC, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000; 101: 2734-41.
27. Hombach V, Grebe O, Merkle N, Waldenmaier S, Höher M, Kochs M, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005; 26: 549-57.
28. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-8.
29. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-72.
30. Roe M, Ohman E, Maas AC, Christenson RH, Mahaffey KW, Granger CB, et al. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion. J Am Coll Cardiol 2001; 37: 9-18.
31. [Davies CH, Ormerod OJM. Failed coronary thrombolysis. Lancet 1998; 351: 1191-6.
32. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
33. Pfeffer MA, Braunwald E, Moý LA, Basta L, Brown EJ Jr, Cuddy TE, et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
34. Bonarjee VV, Carstensen S, Caidahl K, Nilsen DW, Edner M, Berning J. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. Am J Cardiol 1993; 72(14): 1004-9.
35. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
36. [No author listed] ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
37. Chinese cardiac study collaborative group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-7.
38. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. For the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensinconverting- enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
39. Nicolosi GL, Latini R, Marino P, Maggioni AP, Barlera S, Franzosi MG, et al. The prognostic value of predischarge quantitative twodimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 1996; 17: 1646-56.
40. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-60.
41. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al. Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val- HeFT echocardiographic study. J Am Coll Cardiol 2002; 40: 970-5.
42. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. for the valsartan in acute myocardial infarction trial investigators. Valsartan, captopril, or both in myocardialinfarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
43. Nicolosi G, Golcea S, Ceconi C, Parrinello G, Decarli A, Chiariello M, et al. Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: The PREAMI echo sub-study. Eur Heart J 2009; 30: 1656-65.
44. Thai HM, Van HT, Gaballa MA, Goldman S, Raya TE. Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Am J Physiol 1999; 276: H873-80.
45. Sun Y, Zhang JQ, Zhang J, Ramires FJ, Angiotensin II transforming growth factorbeta1 and repair in the infarcted heart. J Mol Cell Cardiol 1998; 30: 1559-69.
46. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Izumi Y, Takeuchi K, et al. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res 2003; 57: 48-54.
47. Baker KM, Johns DW, Ayers CR, Carey RM. Ischemic cardiovascular complications concurrent with administration of captopril. A clinical note. Hypertension 1980; 2: 73-4.
48. Brivet F, Delfraissy JF, Giudicelli JF, Richer C, Legrand A, Dormont J. Immediate effects of captopril in acute left ventricular failure secondary to myocardial infarction. Eur J Clin Invest 1981; 11: 369-73.
49. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1: 255-9.
50. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319: 80-6.
51. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, et al. Candesartan in Heart failure Assessment of Reduction in Mortality morbidity (CHARM) Investigators Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: Results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110: 2618-26.
52. [ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100, 000 patients in randomized trials. Circulation 1998; 97: 2202-12.
53. Landmesser U, Wollert K, Drexler H. Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res 2009; 81: 519-27.
54. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7.
55. Blocker heart attack trial research group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-14.
56. Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, Vedin A, et al. The göteborg metoprolol trial: Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983; 67: 126-32.
57. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995; 92: 212-8.
58. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36: 2072-80.
59. The CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9 -13.
60. Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lṕez-Sendń J, Sharpe N. For the CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN Echo Substudy. Circulation 2004; 109: 201-6.
61. Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004; 18: 57-66.
62. Ghio S, Magrini G, Serio A, Klersy C, Fucili A, Ronaszeki A, et al. SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27: 562-8.
63. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. For the eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309 -21.
64. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. For the randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
65. Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, et al. AREA IN-CHF Investigators. Antiremodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): Final results. Eur J Heart Fail 2009; 11: 68-76.
66. Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ Res 2005; 96: 151-63.
67. Heineke J, Auger-Messier M, Xu J, Oka T, Sargent MA, York A, et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest 2007; 117: 3198-210.
68. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446: 444-8.
69. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003; 107: 461-8.
70. Yoon YS, Wecker A, Heyd L, Park JS, Tkebuchava T, Kusano K, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005; 115: 326-38.
71. Zeng L, Hu Q, Wang X, Mansoor A, Lee J, Feygin J, et al. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 2007; 115: 1866-75.
72. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001; 104: 1046-52.
73. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrowstemcells to treat acutemyocardial infarction: A systematic review. Eur Heart J 2008; 29: 1807-18.
74. Singh S, Arora R, Handa K, Khraisat A, Nagajothi N, Molnar J, et al. Stem cells improve left ventricular function in acute myocardial infarction. Clin Cardiol 2009; 32: 176-80.
75. Zhang S, Sun A, Xu D, Yao K, Huang Z, Jin H, et al. Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: A pooled subgroup analysis of randomized controlled trials. Clin Cardiol 2009; 32: 458-66.
76. Zhang SN, Sun AJ, Ge JB, Yao K, Huang ZY, Wang KQ, et al. Intracoronary autologous bone marrow stem cells transfer for patients with acute myocardial infarction: A meta-analysis of randomised controlled trials. Int J Cardiol 2009; 136: 178-85.
77. Kang S, Yang YJ, Li CJ, Gao RL. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: A systematic review and meta-analysis for randomized controlled trials. Coron Artery Dis 2008; 19: 327-35.
78. Hristov M, Heussen N, Schober A, Weber C. Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: A meta-analysis. J Cell Mol Med 2006; 10: 727-33.
79. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: Acollaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007; 50: 1761-7.
80. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161-72.
81. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and longterm prognostic implications. Circulation 2002; 106: 2351-7.
82. ] Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005; 111: 2837-49.
83. Mengozzi G, Rossini R, Palagi C, Musumeci G, Petronio A, Limbruno U, et al. Usefulness of intravenous myocardial contrast echoardiography in the early left ventricular remodeling in acute myocardial infarction. Am J Cardiol 2002; 90: 713-9.
84. Sun L, Zhang T, Lan X, Du G. Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: A metaanalysis. Clin Cardiol 2010; 33: 296-302.
85. Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ Res 2005; 96: 151-63.
86. Agbulut O, Vandervelde S, Al Attar N, Larghero J, Ghostine S, Leobon B, et al. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol 2004; 44: 458-63.
87. Baslam LB,Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemicmyocardium. Nature 2004; 428: 668-73.
88. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002; 360: 427-35.
89. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, et al. Bonemarrow derived cells do not incorporate into the adult growing vasculature. Circ Res 2004; 94: 230-8.
90. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94: 678-85.
91. Heil M, Ziegelhoeffer T, Mees B, Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: Bone marrow delivers software not hardware. Circ Res 2004; 94: 573-4.
92. Prabhu SD. Nitric oxide protects against pathological ventricular remodeling: Reconsideration of the role of NO in the failing heart. Circ Res 2004; 94: 1155-57.
93. Kanno S, Lee PC, Zhang Y, Ho C, Griffith BP, Shears LL, et al. Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation 2000; 101: 2742-8.
94. Massion PB, Balligand JL. Relevance of nitric oxide for myocardial remodeling. Curr Heart Fail Rep 2007; 4: 18-25.
95. Kaesemeyer, W.H. Method of stimulating nitric oxide synthase. US6465516 (2002).
96. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer ave9488 after experimental myocardial infarction. Circulation 2008; 118: 818-27.
97. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007; 100: 1089-98.
98. Gilson WD, Epstein FH, Yang Z, Xu Y, Prasad KM, Toufektsian MC, et al. Borderzone contractile dysfunction is transiently attenuated and left ventricular structural remodeling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice. J Am Coll Cardiol 2007; 50: 1799-807.
99. Delgado, R.M., III Willerson, J.T. Treatment of heart disease with COX-2 inhibitors. US6323226 (2001).
100. Brown EJ Jr, Kloner RA, Schoen FJ, Hammerman H, Hale S, Braunwald E. Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am J Cardiol 1983; 51: 877-83.
101. Hammerman H, Kloner RA, Schoen FJ, Brown EJ Jr, Hale S, Braunwald E. Indomethacin-induced scar thinning after experimental myocardial infarction. Circulation 1983; 67: 1290-5.
102. Timmers L, Sluijter JP, Verlaan CW, Steendijk P, Cramer MJ, Emons M, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007; 115: 326-32.
103. Straino S, Salloum FN, Baldi A, Ockaili RA, Piro M, Das A, et al. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol 2007; 50: 571-7.
104. Plat, F., Campion, G.V. Combinations of valsartan with COX-2 inhibitors. US 20060079579 (2006).
105. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-30.
106. Spinale FG, Escobar GP, Hendrick JW, Clark LL, Camens SS, Mingoia JP, et al. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: Differential effects on short and long-term survival. J Pharmacol Exp Ther 2006; 318: 966-73.
107. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. Anakinra a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117: 2670-83.
108. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, et al. VCU-ART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010; 105: 1371-7.
109. Frangogiannis NG, Mendoza LH, Lindsey ML, Ballantyne CM, Michael LH, Smith CW, et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 2000; 165: 2798-808.
110. Yao L, Huang K, Huang D, Wang J, Guo H, Liao Y. Acute myocardial infarction induced increases in plasma tumor necrosis factor-alpha and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell. Int J Cardiol 2008; 123: 366-8.
111. Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 2000; 32: 386-9.
112. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodelling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-73.
113. Nakaya R, Uzui H, Shimizu H, Nakano A, Mitsuke Y, Yamazaki T, et al. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 2005; 105: 67-73.
114. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006; 97: 1165-71.
115. Nagashima M, Koyanagi R, Kasanuki H, Hagiwara N, Yamaguchi J, Atsuchi N, et al. Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction: The Heart Institute of Japan, Department of Cardiology statin evaluation program. Am J Cardiol 2007; 99: 1523-8.
116. Murray DB, Gardner JD, Brower GL, Janicki JS. Effects of nonselective endothelin-1 receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats. Am J Physiol Heart Circ Physiol 2008; 294: H1251-57.
117. Duchen MR, McGuinness O, Brown LA, Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 1993; 27: 1790-4.
118. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-81.
119. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, et al. Postconditioning the human heart. Circulation 2005; 112: 2143-8.
120. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Intravenous atrial natriuretic peptide prevents leftventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-6.
121. Kuga H, Ogawa K, Oida A, Taguchi I, Nakatsugawa M, Hoshi T, et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J 2003; 67: 443-8.
122. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007; 49: 667-74.
123. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008; 29: 1485-94.
124. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet 2007; 370: 1483-93.
125. Blackburn, B., Sabbah, H.U.S. Method of reversing left ventricular remodelling. US20090176772 (2009).
126. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003; 107: 618-25.
127. Mukherjee R, Rivers WT, Ruddy JM, Matthews RG, Koval CN, Plyler RA, et al. Long-term localized high-frequency electric stimulation within the myocardial infarct. Circulation 2010; 122: 20-32.
128. Kramer, A.P., Salo R.W., Spinelli, J.C., Kenknight, B.H. Apparatus and method for reversal of myocardial remodeling with electrical stimulation. US20090254141 (2009).
129. Mower, M.M. System and method for managing detrimental cardiac remodelling. US7440800 (2008).
130. Ferrazzi P. Endoventicular device for the treatment and correction of cardiomyopathies. US7731649 (2010).
131. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The task force on the management of st-segment elevation acute myocardial infarction of the european society of cardiology. Eur Heart J 2008; 29: 2909-45.
132. Tarantini G, Napodano M, Gasparetto N, Favaretto E, Marra MP, Cacciavillani L. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron Artery Dis 2010; 21: 78-86.
133. American Heart Association. Heart disease and stroke statistics-update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
134. Jugdutt B, Jelani A. Aging and defective healing, adverse remodeling, and blunted post-conditioning in the reperfused wounded heart. J Am Coll Cardiol 2008; 51: 1399-403.
135. Bujak M, Kweon HJ, Chatila K, Li N, Taffet G, Frangogiannis NG. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J Am Coll Cardiol 2008; 51: 1384-92.
136. Jugdutt BI. Ventricular remodeling post-infarction and the extracellular collagen matrix. When is enough enough? Circulation 2003; 108: 1395-403.
137. Ertl G, Frantz S. Healing after myocardial infarction. Cardiovasc Res 2005; 66: 22-32.